// archives

Archive for October, 2003

REDISCOVERING NATURAL PRODUCTS

REDISCOVERING NATURAL PRODUCTS
Cast aside for years, natural products drug discovery appears to be reclaiming attention and on the verge of a comeback

Biotech funding on track to bounce back

Biotech funding on track to bounce back
It’s not over yet, but 2003 already looks like a banner year for biotechnology funding in the United States, according to a survey released yesterday by the accounting firm Ernst & Young.

Popping a pill could fix gene defect

Popping a pill could fix gene defect
Simply popping a pill might be enough to overcome the type of genetic defect responsible for many cases of cystic fibrosis, muscular dystrophy and haemophilia. An experimental drug called PTC124 produces a working protein even though the gene remains defective.

Monsanto Overhauling Businesses

Monsanto Overhauling Businesses
Monsanto, the world’s leading agricultural biotechnology company, says it is abandoning efforts to produce pharmaceuticals in genetically engineered crops to focus on businesses that could pay off sooner.

Cloning Remains a Meaty Issue

Cloning Remains a Meaty Issue
The Food and Drug Administration soon will decide whether the meat in your Philly cheese steak or your barbecue spareribs could come from a cloned animal.
Because of safety concerns, the FDA has barred the handful of companies that clone farm animals from selling them for meat. But since early this year, [...]

Sabotage of biotech firms grows

Sabotage of biotech firms grows
A growing militant movement opposed to genetic engineering in agriculture and medicine is turning to violent and criminal sabotage — from the bombing of a Bay area biotech company to the destruction of genetically modified crops.
As a result, targeted companies aren’t just taking extra security precautions but also often altering business [...]